New clinical data presented by Eli Lilly at ESMO 2026 highlights the promising efficacy of olomorasib, an investigational treatment targeting KRAS G12C-mutant non-small cell lung cancer (NSCLC). The data reveals durable first-line activity, showing encouraging response rates and a favorable safety profile in patients with this specific genetic mutation. KRAS G12C mutations are a significant driver of NSCLC, and olomorasib’s targeted approach offers a novel therapeutic option for patients who have limited alternatives. These findings mark an important advancement in precision oncology, emphasizing Lilly’s commitment to developing treatments that address unmet medical needs. With ongoing trials, olomorasib may soon provide a new standard of care for patients battling KRAS G12C-mutant NSCLC. The results presented at ESMO 2026 bolster optimism for improved outcomes in lung cancer therapy through innovative, mutation-focused interventions.
Eli LillyNew data shows dramatic one-year drop in federal crime after Trump’s first year of the second term
October 28, 2026
New federal crime statistics reveal a significant decline in crime rates following President Trump’s first year of his second term, highlighting a dramatic one-year drop.